Zambia Emory HIV Research Project - Ndola CoVPN CRS
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leader, CRS
HVTN 135, NCT04607408: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

Completed
1
38
RoW
CH505TF gp120, GLA-SE adjuvant, Placebo
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
07/24
07/24
CoVPN3008TB, NCT06585683: Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008

Recruiting
N/A
6000
RoW
Clinical Evaluation at Day 4, Laboratory Evaluation at Day 4, Clinical Evaluation at week 26, Laboratory Evaluation at week 26
COVID-19 Prevention Network, National Institute of Allergy and Infectious Diseases (NIAID), Medical Research Council, South Africa
Tuberculosis
10/25
10/25
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Completed
N/A
13
RoW
Analytical Treatment Interruption
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
02/25
02/25
Coordinator, CRS
CoVPN3008TB, NCT06585683: Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008

Recruiting
N/A
6000
RoW
Clinical Evaluation at Day 4, Laboratory Evaluation at Day 4, Clinical Evaluation at week 26, Laboratory Evaluation at week 26
COVID-19 Prevention Network, National Institute of Allergy and Infectious Diseases (NIAID), Medical Research Council, South Africa
Tuberculosis
10/25
10/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leader, CRS
HVTN 135, NCT04607408: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

Completed
1
38
RoW
CH505TF gp120, GLA-SE adjuvant, Placebo
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
07/24
07/24
CoVPN3008TB, NCT06585683: Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008

Recruiting
N/A
6000
RoW
Clinical Evaluation at Day 4, Laboratory Evaluation at Day 4, Clinical Evaluation at week 26, Laboratory Evaluation at week 26
COVID-19 Prevention Network, National Institute of Allergy and Infectious Diseases (NIAID), Medical Research Council, South Africa
Tuberculosis
10/25
10/25
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Completed
N/A
13
RoW
Analytical Treatment Interruption
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
02/25
02/25
Coordinator, CRS
CoVPN3008TB, NCT06585683: Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008

Recruiting
N/A
6000
RoW
Clinical Evaluation at Day 4, Laboratory Evaluation at Day 4, Clinical Evaluation at week 26, Laboratory Evaluation at week 26
COVID-19 Prevention Network, National Institute of Allergy and Infectious Diseases (NIAID), Medical Research Council, South Africa
Tuberculosis
10/25
10/25

Download Options